Abstract
Introduction
KL-6 is a mucinous high molecular weight glycoprotein that was originally discovered as a circulating adenocarcinoma-associated antigen by Kohno and coworkers (1) . The epitope recognized by anti-KL-6 monoclonal antibody has been shown to belong to the MUC1 gene family (2) . This epitope is detected mainly in alveolar typeII cells and bronchiolar epithelial cells (3) (4) (5) . The serum levels of KL-6 are elevated in patients with idiopathic pulmonary fibrosis (IPF), radiation pneumonitis, active hypersensitivity pneumonitis, pulmonary sarcoidosis, pneumocystis carinii pneumonia, and advanced pulmonary tuberculosis (5) (6) (7) (8) . The serum levels of KL-6 are not elevated in patients with bacterial pneumonia or emphysema. The serum levels of KL-6 are useful biomarkers for the activity of interstitial pneumonias (IP).
Surfactant proteins (SP) are categorized into four types: A, B, C, and D. SP-A and SP-D are hydrophilia and belong to the collectin subgroup of the C-type lectin superfamily (9) . They are very specific and are produced only in the lung by two types of epithelial cells, clara and alveolar type II cells (10) (11) (12) . These surfactant proteins function in the local immune system of the lung (13) . The serum levels of SP-A and SP-D are elevated in patients with IP. The serum levels of SP-A and SP-D are useful biomarkers and prognostic factors for the activity of IP, as are those of .
Several studies have measured the levels of KL-6, SP-A, and SP-D in the bronchoalveolar lavage fluid (BALF) of IPF patients in attempt to understand how those levels become elevated (14) (15) (16) . It has been thought that the destruction of the alveolar epithelium and endothelium might cause hyperlucent blood. But little is known about the roles of these three molecules or the mechanisms underlying those roles.
The concept of acute eosinophilic pneumonia (AEP) was suggested by Allen and colleagues in 1989 (17) . AEP has an acute onset, usually less than a week. Patients present respiratory insufficiency, hypoxemia, fever, diffuse pulmonary infiltrates, increased numbers of eosinophils in BALF (of more than 25%), and no evidence of infection or previous atopic illness. It is also characterized by a rapid response to corticosteroids with resolution of symptoms and the improvement of radiographic abnormality without fibrosis (17, 18) . To our knowledge, no English-language reports have discussed KL-6, SP-A, or SP-D in both serum and BALF of AEP cases. In the present, we examined the clinical roles of the levels of KL-6, SP-A, and SP-D in the sera and BALF of AEP patients and investigated how differences in those levels reflect the pathology and natural progress compared to other IP, as judged by the relationships among these biomarkers.
Materials and Methods

Study subjects
We conducted a retrospective study of 5 patients with AEP who were inpatients at Jichi Medical School Hospital between 1997 and 2002. They included 1 male and 4 females aged 19±4 year (mean±SD) (range: 15-25 year). Four of the subjects were current smokers and 1 was never a smoker. The diagnosis of AEP was established by a combination of medical history, physical examination, laboratory data, chest roentgenograms, chest computed tomography (CT), BALF findings, and Allen's criteria (18) . BAL was performed in all cases upon admission. All cases showed a high percentage (more than 25%) of eosinophils in BALF cells. Three of the patients showed spontaneous improvement (cases 1-3 in Table 1 ), and the other two received corticosteroid therapy for a few days (cases 4, 5 in Table 1 ). At the time samples were retrieved, one patient was receiving corticosteroid therapy. The peripheral venous blood samples on admission were centrifuged at 3,000 rpm for 10 minutes, and the serum samples were frozen and stored at -20°C until used.
Analysis of BALF cells
We used a bronchoscope and collected BALF using three 50 ml aliquots of physiological saline. In 4 of the patients, the right upper lobe was the lavage site. In the remaining patient the right middle lobe was used, because an abnormal shadow was seen most strongly there on chest CT. BALF was filtered through a sterile gauze to eliminate mucus. The cells were counted with a hemocytometer, and each cell was classified using Wright-Giemsa staining. We counted more than 500 stained cells and measured the percentage of each type. The CD4/CD8 ratio was measured by flow cytometry. Each of the other BALF samples was aliquoted and centri- fuged at 1,200 rpm for 10 minutes, and the supernatant fluids were immediately frozen at -20°C until used.
Biomarker measurement
The serum and BALF conservation samples of each AEP patient were dissolved, and KL-6, SP-A, and SP-D were measured for comparison. Unfortunately, in 1 case the BALF quantity was inadequate to measure SP-A, so SP-A levels were measured in the BALF of only 4 cases. All 7 control subjects were normal volunteers who received a bronchoscopy. KL-6 levels were measured by electrochemiluminescence immunoassay (ECLIA) kits (Eitest KL-6, Eisai, Tokyo, Japan) that were based on sandwich-type linked immunosorbent assay using the KL-6 antibody according to the manufacturer's protocol. SP-A levels were measured by enzyme-linked immunosorbent assay (ELISA) kits (SP-A test, Kokusai International Reagents Corp., Kobe, Japan). SP-D levels were measured by enzyme-linked immunosorbent assay (ELISA) kits (SP-D ELISA, Yamasa Corp., Tokyo, Japan). We compared the KL-6, SP-A, and SP-D levels in BALF between the AEP and control subjects, and examined correlations among KL-6, SP-A, and SP-D serum and BALF levels in the AEP patients.
Statistical analysis
Data are shown as means±SD. Differences between two variables were assessed with the Mann-Whitney U-test. Correlations were analyzed with Spearman's rank correlation coefficient. Statistical significance was defined as p<0.05.
Results
KL-6, SP-A, and SP-D in serum and BALF
BALF cell components are summarized in Table 1 . BALF showed an increase in total cell count with eosinophilia and lymphocytosis. In all of the patients, the percentage of eosinophils in BALF was more than 40%. The concentrations of KL-6, SP-A, and SP-D were measured by ELISA. KL-6 levels in the sera of the AEP patients were 164±34 U/ml (range, 112-205 U/ml) and were within the 500 U/ml established cut-off value (19) (Fig. 1A) . KL-6 levels in the BALF of the AEP patients did not differ from those of the control group (p=0.570, AEP vs control subjects, 161±74 U/ml vs 195±2.4 U/ml) ( Fig. 2A) . SP-A levels in the sera of the AEP patients were 58±23 ng/ml (range, 27.3-86.9 ng/ml) and tended to be slightly higher than the 43.8 ng/ml established cut-off value (18) (Fig. 1B) . SP-A levels in the BALF of the AEP patients were significantly higher than those of the control group (p<0.05, AEP vs control subjects, 3,461± 2,449 ng/ml vs 1,209±28 ng/ml) (Fig. 2B) . SP-D levels in the sera of AEP patients were 261±104 ng/ml (range, 138-416 ng/ml) and were higher than the 110 ng/ml established cut-off value (18) (Fig. 1C) . SP-D levels in the BALF of the AEP patients were significantly higher than those of the control group (p<0.05, AEP vs control subjects, 1,693±2,233 ng/ml vs 196±2.4 ng/ml) (Fig. 2C) .
Relationships between KL-6, SP-A, and SP-D in sera or BALF
The relationships between KL-6, SP-A, and SP-D levels in the sera or BALF of the AEP patients were analyzed using cally positive correlation between serum SP-A and serum SP-D (p=0.048, r=0.885). But SP-A and SP-D levels in BALF did not show a statistically positive correlation (p=0.704, r=0.362). There was no apparent correlation between KL-6 and SP-A or SP-D in sera or in BALF. To evaluate whether or not these biomarkers reflected increased lung permeability in the AEP patients, we measured the concentration of albumin in BALF and found that SP-D (p<0.001, r=0.992) levels, but not the levels of SP-A (p=0.735, r=0.326) or KL-6 (p=0.785, r=-0.290), statistically correlated with the albumin concentration. Other factors in BALF, such as total cell, eosinophil, and lymphocyte counts, did not correlate with KL-6, SP-A, or SP-D (data not shown). Likewise, in the sera there was no correlation between KL-6, SP-A, or SP-D on the one hand and CRP or LDH on the other (data not shown).
Serum KL-6, SP-A, or SP-D and clinical courses
All of the AEP patients showed clinical improvement, defined as improvement in both chest radiological findings and clinical laboratory examinations with or without glucocorticosteroid therapy. For two of the patients, serum samples at two points-on admission and 2 months after-were obtained and compared. In those patients, the serum SP-A and SP-D levels decreased until reaching normal levels at 2 months. In case 4, KL-6 level was 210 U/ml, SP-A level was 18.2 ng/ml, SP-D level was 100 ng/ml on 2 months after recovery. In case 5, KL-6 142 U/ml, SP-A level was 37.8 ng/ml, SP-D level was 38.7 ng/ml on 2 months after recovery.
Discussion
We demonstrated that levels of SP-A and SP-D, but not of KL-6, were significantly increased in the BALF and sera of AEP patients compared with the controls. SP-A and SP-D levels were significantly correlated in sera, but not in BALF. Furthermore, the increased levels of serum SP-A and SP-D in AEP patients fell to within cut-off levels after clinical improvement. Levels of SP-D, but not of SP-A or KL-6, were significantly correlated with the concentration of albumin in BALF. Since these markers are specifically derived from epithelial cells, it is considered that SP-A and SP-D levels in serum and BALF reflect damage to or release of these markers from epithelial cells due to the inflammatory response in AEP.
The accumulation of eosinophils in the lung is thought to be a principal component of the pathogenesis of eosinophilic pneumonia, and eosinophil-derived proteins are likely involved in producing the lung injury that results from eosinophilic pneumonia (20) . The albumin levels in BALF are more likely to be a marker of increased lung permeability as a consequence of damage to the alveolar epithelium and endothelium due to the inflammatory response. Although the results of the present study demonstrated that SP-A and SP-D levels in the BALF of the AEP patients were significantly elevated, BALF levels of SP-D, but not of SP-A, were correlated with the BALF albumin concentration in those patients. Therefore, SP-D levels might appear to be more sensitive than SP-A levels at reflecting the damage to or release of these molecules from epithelial cells as a consequence of eosinophilic inflammation in AEP lungs. The mechanism by which serum SP-A and SP-D levels are elevated in patients with interstitial lung disease has been thought to be that alveolar type II cells cause hyperplasia from stimulation, such as through inflammation, and generate the creation of biomarkers; in addition, the destruction of alveolar epithelium and endothelium might cause hyperlucent into blood (14, 21) . Furthermore, the molecular weight of a completed unit of SP-A and SP-D is estimated to be 650 kd and 540 kd, respectively, so SP-D is a slightly smaller than SP-A (22, 23) . Considering these mechanism, these differences between BALF and serum levels of SP-A and SP-D in AEP patients might be due to the grade of damage to bronchiolar epithelia. This study could not completely identify the reason for the differences between SP-A and SP-D levels in the BALF of the AEP patients. However, given the small number of patients examined, a larger confirmatory study is necessary to ascertain how applicable these results are to AEP in general.
KL-6 causes chemotaxis of fibroblast and induction of fibrosis in patients with interstitial pneumonias (14) . Reports have demonstrated increased KL-6 levels in the BALF of fibrotic interstitial lung disease, such as IPF or sarcoidosis (7, 14) . The serum levels of KL-6 in patients with nonfibrotic interstitial lung disease, such as bronchiolitis obliterans organizing pneumonia (BOOP) or eosinophilic pneumonia (EP), did not differ from those of normal control subjects. Ohnishi et al have shown that serum KL-6 levels were within the normal range in the BOOP or EP pattern in patients with drug-induced pneumonitis (24) . In the cases of elevated KL-6 levels in BALF, the damaged area in the lung would be spread not only to pulmonary alveolus levels, but also to bronchiolar levels. Moreover, the grade of damage would be severe and would lead to pulmonary fibrosis. AEP does not lead to pulmonary fibrosis in general, and the present study demonstrated that KL-6 levels in the BALF and sera of the AEP patients were not increased compared with the control subjects. Non-fibrotic interstitial lung disease, including AEP, might not generate the creation of KL-6, because the grade of damage in bronchiolar epithelia is not severe.
Although it is difficult to determine the mechanisms and roles of increased levels of KL-6, SP-A, or SP-D in the BALF of patients with various lung diseases, it is speculated that these biomarkers in BALF might reflect pathological differences and grades of damage in bronchiolar epithelia, as shown in Table 2 . Increased KL-6 levels have been found in the BALF of patients with a fibrotic interstitial lung disease, such as IPF or sarcoidosis (7, 14) . On the other hand, SP-A or SP-D levels in BALF from patients with IPF or interstitial pneumonia with collagen vascular disease (CVD-IP) have been reported to be either reduced (25) (26) (27) or unchanged (28, 29) . Reduced or unchanged SP-A and SP-D levels in BALF from clinically stable patients with cystic fibrosis have also been reported, but increased levels have been found when the disease progressed as a result of infection (30, 31) . SP-A or SP-D levels in BALF of pulmonary sarcoidosis patients have been reported to be increased (7, 32) , unchanged (7), or reduced (27, 29) . Increased SP-A or SP-D levels in BALF of pneumocystis carinii pneumonia (33) and pulmonary alveolar proteinosis (PAP) (29) have been reported. Reduced SP-A or SP-D levels in BALF from patients with acute respiratory distress syndrome (ARDS) (34) and bacterial pneumonia (28) have been reported. SP-A levels in BALF from patients with hypersensitivity pneumonitis have been reported to be increased (27) or reduced (33) . The present study demonstrated that levels of SP-A and SP-D, but not KL-6, were significantly increased in the BALF and sera of AEP patients compared with the controls. Further analysis is needed to determine the roles and mechanisms of these biomarker levels in the BALF of patients with interstitial lung disease.
Conclusion
In conclusion, the present results demonstrate that levels of SP-A and SP-D, but not KL-6, in both BALF and sera are significantly increased in patients with AEP. Furthermore, levels of SP-D, but not SP-A or KL-6, were significantly correlated with the concentration of albumin in BALF. Since these markers are specifically derived from epithelial cells, SP-D levels appear to be more sensitive than SP-A levels at reflecting damage to or the release of these markers from epithelial cells caused by the inflammatory response in the lung of acute eosinophilic pneumonia.
